Join AB Science at the Biomed Forum: Your Insider Access to Investment Insights

PRESS RELEASE

AB Science to Attend Biomed Forum Conference

Paris, January 22, 2024, 7 PM CET

AB Science SA (Euronext – FR0010557264 – AB) is excited to announce its participation in the Biomed Forum, a key conference for institutional investors. This event is organized by AllInvest Securities and will take place in Paris on February 4, 2025.

About AB Science
Founded in 2001, AB Science focuses on developing protein kinase inhibitors (PKIs) that play a crucial role in cell signaling. The company aims to tackle severe diseases that have limited treatment options. Our lead compound, masitinib, is already approved for veterinary use and is in development for human treatments in oncology, neurology, inflammation, and viral diseases. Based in Paris, AB Science is listed on Euronext Paris (ticker: AB).

Discover more about our work by visiting our website:
www.ab-science.com.

Forward-looking Statements
This release contains forward-looking statements, which are not guaranteed facts. These include projections, estimates, and expectations about future performance and product development. While we strive for accuracy, these statements carry risks and uncertainties that could result in different outcomes than we anticipate.

Investors should be aware that various factors, including product development challenges and marketing approvals, may affect our results. AB Science is not obliged to update these statements unless required by regulations.

Contact Information:

AB Science
Financial Communication & Media Relations
investors@ab-science.com

• Conference AllInvest VENG VF

Source link

Paris Stock Exchange:AB, AB Science